Total debt declined from $389.3M in 2026Q1 to $167.4M in 2026Q3 and the debt-to-equity ratio fell to 0.13, though a current ratio of 3.95 and $460.7M in cash contrast with an accumulated deficit of roughly -$1.9B.
Legend Biotech Corporation (LEGN) balance sheet — 9-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 |
|---|
| Total Current Assets | 1.14B | 1.25B | 1.28B | 1.5B | 1.1B | 949.85M | 593.94M | 207.1M | 326.96M | 230.9M |
| Cash & Short-Term Investments | 852.5M | 948.6M | 1.12B | 1.31B | 1.03B | 882.39M | 506.07M | 159.18M | 216.18M | 2.12M |
| Cash Only | 460.7M | 901.9M | 286.75M | 1.28B | 786.03M | 688.94M | 456.07M | 83.62M | 210.17M | 2.12M |
| Short-Term Investments | 391.8M | 46.7M | 835.93M | 31M | 239.62M | 193.46M | 50M | 75.56M | 6.01M | 0 |
| Accounts Receivable | 218.9M | 250.3M | 124.89M | 157.06M | 44.52M | 58.55M | 82.62M | 35.76M | 108.57M | 228.74M |
| Days Sales Outstanding | 57.35 | 88.79 | 72.67 | 201.05 | 138.87 | 310.49 | 402.06 | 211.19 | 806.53 | 3.54K |
| Inventory | 39.8M | 32M | 23.9M | 19.43M | 10.35M | 1.75M | 1.8M | 1.16M | 1.14M | 11K |
| Days Inventory Outstanding | 23.49 | 28.62 | 37.19 | 49.18 | 57.82 | - | - | - | - | -41.82 |
| Other Current Assets | 10.1M | 1.6M | 70K | 357K | 1.27M | 1.44M | 0 | 0 | 255K | 760K |
| Total Non-Current Assets | 536.6M | 486.6M | 386.24M | 350.81M | 231.84M | 169.62M | 128.15M | 80.61M | 102.09M | 7.79M |
| Property, Plant & Equipment | 439.5M | 402M | 201.59M | 189.68M | 161.67M | 142.96M | 112.11M | 80.09M | 33.13M | 2.93M |
| Fixed Asset Turnover | 3.12x | 2.56x | 3.11x | 1.50x | 0.72x | 0.48x | 0.67x | 0.77x | 1.48x | 8.06x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 71.3M | 74.6M | 174.22M | 4.06M | 68.69M | 16.8M | 2.85M | 519K | 49K | 2K |
| Long-Term Investments | 5M | 5M | 4.36M | 4.36M | 0 | 4.71M | 0 | 0 | -1.24M | -4.86M |
| Other Non-Current Assets | 25.8M | 5M | 6.06M | 152.42M | 1.49M | 5.15M | 13.19M | 0 | 1.24M | 4.86M |
| Total Assets | 1.68B | 1.73B | 1.67B | 1.85B | 1.33B | 1.12B | 722.09M | 287.71M | 429.05M | 238.69M |
| Asset Turnover | 0.80x | 0.59x | 0.38x | 0.15x | 0.09x | 0.06x | 0.10x | 0.21x | 0.11x | 0.10x |
| Asset Growth % | 4.41% | 3.8% | -9.65% | 38.89% | 18.89% | 55.03% | 150.98% | -32.94% | 79.75% | - |
| Total Current Liabilities | 289.6M | 636.4M | 277.64M | 216.42M | 297.79M | 229.2M | 115.57M | 127.76M | 159.19M | 52.12M |
| Accounts Payable | 72M | 81.2M | 37.19M | 20.16M | 31.69M | 7.04M | 4.91M | 9.59M | 7.32M | 4.33M |
| Days Payables Outstanding | 47.6 | 72.62 | 57.87 | 51.02 | 176.98 | - | - | - | - | -16.48K |
| Short-Term Debt | 44.1M | 319.1M | 0 | 0 | 0 | 0 | 1.79M | 1.03M | 0 | 0 |
| Deferred Revenue (Current) | 18M | 11.3M | 47.41M | 53.01M | 451K | 304K | 55.01M | 46.29M | 40.32M | 30.21M |
| Other Current Liabilities | 1.1M | 1M | 500K | 68K | 67M | 87.9M | 31.45M | 64.22M | 34.16M | 38.08M |
| Current Ratio | 3.95x | 1.96x | 4.62x | 6.92x | 3.69x | 4.14x | 5.14x | 1.62x | 2.05x | 4.43x |
| Quick Ratio | 3.82x | 1.91x | 4.54x | 6.83x | 3.66x | 4.14x | 5.12x | 1.61x | 2.05x | 4.43x |
| Cash Conversion Cycle | 33.24 | 44.79 | 51.99 | 199.21 | 19.7 | - | - | - | - | 19.98K |
| Total Non-Current Liabilities | 119.1M | 95.2M | 351.96M | 380.82M | 288.86M | 124.32M | 6.7M | 282.82M | 261.21M | 174.4M |
| Long-Term Debt | 0 | 0 | 301.2M | 281.33M | 260.93M | 120.46M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 420.81M | 87.2M | 44.61M | 44.17M | 20.04M | 1.59M | 1.91M | 5.08M | 3.94M | 205K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 4.24M | 0 | -213.2M | -174.2M |
| Other Non-Current Liabilities | 7.6M | 8M | -54K | 56K | 233K | 396K | -274.52M | 0 | 0 | 0 |
| Total Liabilities | 408.7M | 731.6M | 629.61M | 597.24M | 586.65M | 353.52M | 122.27M | 410.58M | 420.4M | 226.53M |
| Total Debt | 167.4M | 413.7M | 350.6M | 328.67M | 284.53M | 122.97M | 3.7M | 6.11M | 4.32M | 269K |
| Net Debt | -293.3M | -488.2M | 63.85M | -949.04M | -501.5M | -565.97M | -452.37M | -77.51M | -205.85M | -1.85M |
| Debt / Equity | 0.13x | 0.41x | 0.34x | 0.26x | 0.38x | 0.16x | 0.01x | - | 0.50x | 0.02x |
| Debt / EBITDA | 1.98x | - | - | - | - | - | - | - | 28.97x | 0.02x |
| Net Debt / EBITDA | -3.48x | - | - | - | - | - | - | - | -1381.54x | -0.13x |
| Interest Coverage | 3.27x | -12.21x | -6.32x | -22.87x | -40.29x | -451.44x | -73.20x | -594.23x | -18.71x | - |
| Total Equity | 1.27B | 1B | 1.04B | 1.25B | 744.31M | 765.94M | 597.77M | -122.87M | 8.65M | 12.17M |
| Equity Growth % | 35.99% | -3.69% | -16.85% | 68.12% | -2.82% | 28.13% | 586.51% | -1520.61% | -28.91% | - |
| Book Value per Share | 6.57 | 5.44 | 5.69 | 7.11 | 4.68 | 5.44 | 5.06 | -0.93 | 0.09 | 0.09 |
| Total Shareholders' Equity | 1.27B | 1B | 1.04B | 1.25B | 744.31M | 765.94M | 597.77M | -122.87M | 8.65M | 12.17M |
| Common Stock | 100K | 100K | 37K | 36K | 33K | 31K | 27K | 20K | 20K | 20K |
| Retained Earnings | -1.93B | -1.96B | -1.66B | -1.48B | -966.46M | -520.11M | -116.53M | -127.28M | 5.69M | 8.47M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 122.6M | 122.2M | -68.16M | 98.92M | 14.67M | 4.86M | 5.96M | 485K | 8.63M | -236K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying LEGN stock.
As of 2025, Legend Biotech Corporation (LEGN) had total assets of $1.73B including $1.25B in current assets.
Legend Biotech Corporation (LEGN) carries total debt of $413.7M, offset by $948.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Legend Biotech Corporation (LEGN) has total shareholders' equity (book value) of $1.00B ($5.44 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Legend Biotech Corporation (LEGN) reported a current ratio of 1.96x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Persistent cash burn despite revenue
Balance Sheet Rebuilding Through Cash Accumulation
Based on reported quarterly figures, LEGN's cash balance rose from $201.3M in 2024Q2 to $460.7M in 2026Q3, while equity moved from roughly $1.2B to $1.3B, suggesting the balance sheet has strengthened in liquidity terms over the period.
The increase in cash appears to reflect a combination of collaboration receipts and capital raising rather than organic free cash flow, given that operating cash flow remained negative across most observed quarters. Total liabilities have also declined from $639.2M to $408.7M, which may indicate deleveraging or the settlement of deferred obligations. Investors should monitor whether the cash build is sustained once milestone-driven inflows normalize.
Leverage Falling as Debt Retires
As reported in financial statements, LEGN's total debt declined from $389.3M in 2026Q1 to $167.4M in 2026Q3, lowering the debt-to-equity ratio from 0.40 to 0.13 and reducing refinancing exposure.
The reduction in D/E to 0.13 appears to be a deliberate deleveraging rather than a forced restructuring, though the reported figures do not disclose the repayment source or terms. Lower leverage improves flexibility, but the persistence of negative operating cash flow means the company still depends on external funding or partner receipts for its obligations. The debt trajectory warrants continued monitoring alongside cash burn.
Strong Coverage but Burn-Dependent Runway
Based on reported figures, LEGN's current ratio stood at 3.95 in 2026Q3, down from 5.20 in 2025Q1, with $460.7M in cash providing a substantial buffer against near-term operating shocks.
A current ratio near 4 indicates ample short-term coverage, though the decline from above 5 suggests current liabilities have grown relative to current assets over the last several quarters. The true runway depends on quarterly operating cash burn, which the reported data indicates has been persistently negative. Liquidity appears adequate today, but its durability hinges on whether operating losses narrow.
Accumulated Deficit Dwarfs Equity Base
According to reported balance sheets, LEGN carries retained earnings of approximately -$1.9B against equity of about $1.3B, indicating that paid-in capital has funded a very large cumulative loss history.
The gap between accumulated deficit and equity signals that the company has relied heavily on external capital to finance its development and commercial build-out. Equity quality is therefore driven by new capital contributions rather than retained profitability. Stock-based compensation also contributes to equity dilution over time, which investors should weigh against the reported improvement in net income.
Reported Net Income Masks Weak Cash Quality
As reported in financial statements, LEGN posted $51.7M of net income in 2026Q3 while operating cash flow was negative at -$35.9M, a divergence that may make headline earnings misleading.
The gap between net income and operating cash flow suggests that working capital movements and non-cash items, including stock-based compensation, are carrying a large share of reported results. Balance sheet strength partly reflects capital raised and milestone timing rather than self-funded operations. Analysts should treat the improved balance sheet as dependent on continued partner and capital market access until cash generation becomes consistent.